JNJ•benzinga•
Johnson & Johnson Says TAR-200 Monotherapy Shows Highest Complete Response With Sustained Benefits In 12-month Data From Phase 2B SunRISe-1 Study (Cohort 2)
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 21, 2025 by benzinga